Follow The Filings

TXMD TherapeuticsMD

TherapeuticsMD earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TXMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TXMD insider trades
  • $14K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Tommy G Thompson Director
    Buy
    $14K 8,400 shares at $1.67 +57% to stake
    Traded Dec 23, 2025 Filed Dec 29, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
SCHEDULE 13G — Filing Doc
10-K/A ANNUAL REPORT Filing Doc
10-K ANNUAL REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
DEF 14A PROXY STATEMENT Filing Doc
DEFA14A PROXY STATEMENT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
10-K/A AMENDMENT NO. 1 TO FORM 10-K Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K ANNUAL REPORT Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.